Tracked deals
20
20 tracked deals across 2013-2025.
Biotechnology Buyers & Acquisitions in Washington
Buyer mix
Strategic-led
21 strategic · 5 pe
Top trend
Volume peaked in 2023
6 tracked deals announced in 2023.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Alcon | 1 | Global leader in eye care providing surgical and vision-c... | Strategic |
| Amgen Inc. | 1 | Global biotechnology company that discovers, develops, ma... | Strategic |
| Ampersand Capital Partners | 1 | Middle-market private equity firm focused on growth-orien... | PE |
| AnaBios Corporation | 1 | Pre-clinical contract research organization (CRO) special... | Strategic (PE-backed) |
| AstraZeneca | 1 | Global, science‑led biopharmaceutical company focused on ... | Strategic |
| Brooks Automation, Inc. | 1 | Global provider of automation, vacuum and instrumentation... | Strategic |
| Cambridge Companies SPG | 1 | Investment firm providing growth equity and private inves... | PE |
| Convent Capital | 1 | Amsterdam-based investment firm focused on growth capital... | PE |
| Discovery Life Sciences | 1 | Provider of biospecimen inventory and multi‑omic biomarke... | Strategic |
| Eni Next | 1 | Corporate venture arm of Eni S.p.A investing in energy, c... | Strategic |
Acquisition Volume in Biotechnology in Washington by Year
Last 7 years
Supporting Data
Recent Transactions
-
November 4, 2025
- Buyer
- QIAGEN N.V.
- Target
- Parse Biosciences
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
QIAGEN entered into a definitive agreement to fully acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell sequencing market. The deal is expected to close in late 2025/December 2025 for an upfront payment of approximately $225 million in cash, plus up to $55 million in milestone payments.
-
March 26, 2025
- Buyer
- Alcon
- Target
- Aurion Biotech, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.
-
February 5, 2025
- Buyer
- Cambridge Companies SPG, Eni Next, Milliken & Company, KIRKBI Climate, Convent Capital, SWEN Capital Partners' Blue Ocean Fund, MBX Capital, IDO Investments (Oman Investment Authority)
- Target
- Tidal Vision
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Growth capital
Tidal Vision raised an oversubscribed $140 million Series B led by Cambridge Companies SPG with participation from Eni Next, Milliken & Company, KIRKBI Climate, Convent Capital, SWEN Capital Partners' Blue Ocean Fund, MBX Capital, IDO Investments (Oman Investment Authority) and others. The growth equity will fund expanded commercial-scale production, new facilities in Europe and the U.S. (Texas and Ohio), and accelerated R&D to scale chitosan-based biomolecular solutions for water treatment, agriculture, and materials markets globally.
-
December 12, 2024
- Buyer
- Tenpoint Therapeutics Limited
- Target
- Visus Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.
-
October 29, 2024
- Buyer
- Quris-AI
- Target
- Nortis (formerly Numa Biosciences, Inc.)
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Quris-AI has acquired the assets of Nortis (formerly Numa Biosciences) to integrate Nortis's Kidney-on-Chip microphysiology systems into Quris-AI's Bio-AI clinical prediction platform. The acquisition will combine Nortis's validated in-vitro kidney models with Quris-AI's machine-learning models and expand access to publicly funded MPS data while continuing collaborations with research institutes, the FDA and pharmaceutical partners.
-
April 10, 2024
- Buyer
- Vertex Pharmaceuticals Incorporated
- Target
- Alpine Immune Sciences, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for $65 per share in cash, valuing the deal at approximately $4.9 billion. The transaction is unanimously approved by both boards and is anticipated to close later in the second quarter of 2024.
-
April 3, 2024
- Buyer
- Genmab A/S
- Target
- ProfoundBio, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Genmab (Nasdaq: GMAB) and ProfoundBio announced a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction valued at $1.8 billion. The deal will expand Genmab’s mid- to late-stage oncology pipeline by adding ProfoundBio’s next-generation antibody-drug conjugate (ADC) programs, including Rina-S.
-
December 14, 2023
- Buyer
- Pfizer Inc.
- Target
- Seagen Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Pfizer completed its acquisition of Seagen, acquiring all outstanding common stock of Seagen for $229 per share in cash, valuing the enterprise at approximately $43 billion. The combination is intended to strengthen Pfizer’s oncology portfolio by adding Seagen’s proprietary antibody-drug conjugate (ADC) technology and in-line medicines.
-
December 12, 2023
- Buyer
- AstraZeneca
- Target
- Icosavax
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.
-
June 26, 2023
- Buyer
- Swedish Orphan Biovitrum AB (Sobi)
- Target
- CTI BioPharma Corp.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.
-
June 12, 2023
- Buyer
- Novartis AG
- Target
- Chinook Therapeutics, Inc.
- Seller
- Chinook Therapeutics stockholders
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.
-
April 11, 2023
- Buyer
- Discovery Life Sciences
- Target
- ReachBio Research Labs
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.
-
April 4, 2023
- Buyer
- AnaBios Corporation, Ampersand Capital Partners
- Target
- Cell Systems
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Addon
AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.
-
September 7, 2022
- Buyer
- Roche
- Target
- Good Therapeutics
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.
-
March 30, 2021
- Buyer
- Amgen Inc.
- Target
- Rodeo Therapeutics Corporation
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Amgen Inc. has agreed to acquire privately held Rodeo Therapeutics, a Seattle-based biopharmaceutical company focused on small-molecule modulators of prostaglandin biology, including a lead 15-PGDH program. The deal includes a $55 million upfront cash payment plus up to $666 million in potential contingent milestone payments and is intended to expand Amgen's inflammation and tissue-regeneration capabilities.
-
May 27, 2020
- Buyer
- Sensei Biotherapeutics, Inc.
- Target
- Alvaxa Biosciences, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Sensei Biotherapeutics has completed the acquisition of Alvaxa Biosciences, a Seattle-based developer of camelid (alpaca-derived) nanobodies and related discovery libraries. The purchase brings Alvaxa's nanobody libraries, discovery expertise and a partnership with Hope Farms into Sensei's ImmunoPhage platform to expand its immuno-oncology capabilities.
-
February 26, 2020
- Buyer
- Takeda Pharmaceutical Company Limited
- Target
- PvP Biologics, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Takeda Pharmaceutical Company Limited exercised its option to acquire PvP Biologics, Inc. following positive Phase 1 proof-of-mechanism results for TAK-062 (Kuma062), an oral engineered glutenase for celiac disease. The deal includes a pre-negotiated upfront payment and up to $330 million in development and regulatory milestones and brings TAK-062 and TAK-101 into Takeda's gastroenterology pipeline.
-
September 17, 2018
- Buyer
- Thompson Street Capital Partners
- Target
- LifeSpan Biosciences, Inc. (LSBio)
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Thompson Street Capital Partners (TSCP), a St. Louis-based private equity firm, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc. (LSBio), a developer and e‑commerce distributor of antibodies, kits, proteins and related reagents for academic and pharmaceutical research. TSCP said it will support LSBio's strategy to expand its catalog and capabilities organically and via targeted acquisitions; terms were not disclosed.
-
- Buyer
- Probi AB, Probi USA, Inc. (subsidiary of Probi AB)
- Target
- Nutraceutix (TNTGamble, Inc.)
- Seller
- TNTGamble, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Probi AB, via its U.S. subsidiary Probi USA, Inc., signed an asset purchase agreement to acquire the operations of TNTGamble, Inc. (doing business as Nutraceutix) for a preliminary cash purchase price of USD 105 million. The acquisition substantially expands Probi’s North American presence, adds proprietary delivery technology and manufacturing capacity, brings ~200 customers and ~145 employees, and will be financed with cash, a credit facility and a bridge facility to be refinanced by a proposed SEK 600 million rights issue.
-
- Buyer
- Brooks Automation, Inc.
- Target
- Matrical, Inc. (Matrical Bioscience)
- Seller
- Matrical, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Brooks Automation, Inc. (Nasdaq: BRKS) signed a definitive agreement to acquire the assets and business of Matrical, Inc. for approximately $10 million in cash. The Spokane, Washington–based provider of biological sample preparation, management and storage solutions will join Brooks’ Life Science Systems business to expand its capabilities and penetration in the Agbio and broader life sciences markets.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Biotechnology Acquisitions in 2020
Acquisitions in Washington
Private Equity-Backed Acquisitions in Washington
Acquisitions in Washington in 2025